IN2012DN00592A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00592A
IN2012DN00592A IN592DEN2012A IN2012DN00592A IN 2012DN00592 A IN2012DN00592 A IN 2012DN00592A IN 592DEN2012 A IN592DEN2012 A IN 592DEN2012A IN 2012DN00592 A IN2012DN00592 A IN 2012DN00592A
Authority
IN
India
Prior art keywords
oxalate
compositions
methods
present
reducing
Prior art date
Application number
Other languages
English (en)
Inventor
Sidhu Harmeet
Li Qingshan
Blake Cowley Aaron
Golander Carl-Gustaf
Original Assignee
Oxthera Intellectual Property Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/497,275 external-priority patent/US8431122B2/en
Priority claimed from EP09164430.2A external-priority patent/EP2270138B1/fr
Application filed by Oxthera Intellectual Property Ab filed Critical Oxthera Intellectual Property Ab
Publication of IN2012DN00592A publication Critical patent/IN2012DN00592A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN592DEN2012 2009-07-02 2010-07-01 IN2012DN00592A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/497,275 US8431122B2 (en) 2009-07-02 2009-07-02 Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
EP09164430.2A EP2270138B1 (fr) 2009-07-02 2009-07-02 Purification et isolation d'enzymes à dégradation d'oxalate recombinante
PCT/EP2010/003864 WO2011000523A1 (fr) 2009-07-02 2010-07-01 Purification et isolement d’enzymes de recombinaison dégradant l'oxalate, et particules séchées par atomisation contenant ces enzymes

Publications (1)

Publication Number Publication Date
IN2012DN00592A true IN2012DN00592A (fr) 2015-06-12

Family

ID=43028177

Family Applications (1)

Application Number Title Priority Date Filing Date
IN592DEN2012 IN2012DN00592A (fr) 2009-07-02 2010-07-01

Country Status (16)

Country Link
US (1) US20120189604A1 (fr)
EP (1) EP2449098B1 (fr)
JP (2) JP2012531186A (fr)
CN (2) CN104805067A (fr)
BR (1) BRPI1013956B8 (fr)
CA (2) CA2767039C (fr)
DK (1) DK2449098T3 (fr)
ES (1) ES2617917T3 (fr)
HK (1) HK1210805A1 (fr)
HU (1) HUE030905T2 (fr)
IL (1) IL216873A (fr)
IN (1) IN2012DN00592A (fr)
LT (1) LT2449098T (fr)
PL (1) PL2449098T3 (fr)
PT (1) PT2449098T (fr)
WO (1) WO2011000523A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
WO2014113648A1 (fr) 2013-01-18 2014-07-24 Allena Pharmaceuticals, Inc. Oxalate décarboxylase cristallisée et ses procédés d'utilisation
CN103540569A (zh) * 2013-06-05 2014-01-29 黄虹寓 结石酶及其制备方法
EP3003358B1 (fr) * 2013-06-07 2021-03-24 Allena Pharmaceuticals Inc. Compositions et dispositifs de dialyse
CN104673765B (zh) * 2014-12-22 2017-11-17 武汉康复得生物科技股份有限公司 一组在生理pH条件下有活力的草酸氧化酶及其应用
CN114903985A (zh) * 2021-02-10 2022-08-16 宁波倍益嘉生物科技有限公司 一种组合物及其在防治高草酸尿症方面的应用
CN116124853B (zh) * 2022-11-07 2024-01-16 东北农业大学 一种检测草酸的电化学生物传感器、制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486389B2 (en) * 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US6929940B1 (en) * 2002-08-20 2005-08-16 University Of Florida Research Foundation, Inc. Polynucleotides encoding oxalate decarboxylase from Aspergillus niger and methods of use
AU2003274918A1 (en) * 2002-08-20 2004-03-11 University Of Florida Polynucleotide encoding oxalate decarboxylase from aspergillus niger and methods of use
ES2426258T3 (es) * 2005-12-14 2013-10-22 Oxthera Intellectual Property Ab Composiciones farmacéuticas que comprenden bacterias que reducen oxalato
ES2362897T3 (es) * 2005-12-16 2011-07-14 Oxthera, Inc. Composiciones y métodos para reducción del oxalato.
ES2412254T3 (es) * 2006-08-02 2013-07-10 Altus Pharmaceuticals Inc. Oxalato-descarboxilasa cristalizada y métodos de uso

Also Published As

Publication number Publication date
HUE030905T2 (en) 2017-06-28
CA2767039C (fr) 2018-09-04
BRPI1013956A2 (pt) 2019-04-09
CA2767039A1 (fr) 2011-01-06
CN102597225A (zh) 2012-07-18
ES2617917T3 (es) 2017-06-20
HK1210805A1 (en) 2016-05-06
BRPI1013956B1 (pt) 2021-04-06
CN102597225B (zh) 2015-04-29
PL2449098T3 (pl) 2017-06-30
LT2449098T (lt) 2017-05-25
PT2449098T (pt) 2017-03-10
EP2449098A1 (fr) 2012-05-09
JP2016121138A (ja) 2016-07-07
JP6220845B2 (ja) 2017-10-25
WO2011000523A1 (fr) 2011-01-06
IL216873A (en) 2017-07-31
JP2012531186A (ja) 2012-12-10
IL216873A0 (en) 2012-02-29
EP2449098B1 (fr) 2016-12-07
BRPI1013956B8 (pt) 2021-05-25
CA3012811A1 (fr) 2011-01-06
US20120189604A1 (en) 2012-07-26
CN104805067A (zh) 2015-07-29
DK2449098T3 (en) 2017-03-06

Similar Documents

Publication Publication Date Title
MX2012007684A (es) Modificacion covalente ligando dirigida de proteina.
IN2012DN00592A (fr)
MY158325A (en) Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection
WO2010034032A3 (fr) Procédés pour préparer des compositions de polypeptide purifié
MX2012000475A (es) Variantes de plasminogeno y plasmina.
IN2012DN00801A (fr)
MY166552A (en) Infant cereal comprising non-replicating probiotic microorganisms
MY159396A (en) Compositions and methods for antibodies targeting complement protein c5
MY161495A (en) Virus like particle compositions and methods of use
TW200800994A (en) Inhibitors of E1 activating enzymes
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
IL213489A (en) Composition of digestive enzymes for the treatment or prevention of e.coli infections
WO2011072099A3 (fr) Compositions et procédés comprenant des variants de protéase
MX2010003013A (es) Inhibicion de angiogenesis.
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
IN2012DN02471A (fr)
UA103304C2 (ru) Модифицированный белок лецитин-холестерин ацилтрансферазы (lcat)
WO2009150547A3 (fr) Imidazoles à substitution 2-pyridyle en tant qu’alk4 et/ou inhibiteurs d’alk4
MY160560A (en) Compositions and methods for treatment of kidney disorders
MX2011013661A (es) Composiciones y metodos para el tratamiento de esclerosis multiple.
MX2012001306A (es) Inhibicion de matastasis de tumor.
MX2011008179A (es) Peptidos para vacuna.
PH12015501131A1 (en) Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states
MY180681A (en) Compositions and methods for treatment of aortic fibrosis